Novartis | NVS - Loan Capital


Novartis reported $37.45B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Amgen USD 51.86B 27M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
Bausch Health Companies USD 19.88B 20M Jun/2026
Biogen USD 7.29B 1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Canopy Growth CAD 217.12M 7.87M Mar/2026
Drreddys Laboratories INR 12.2B 12.07B Mar/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
J&J USD 37.34B 183M Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Novartis USD 37.49B 42M Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.28B 337.7M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
Phibro Animal Health USD 597.68M 5.92M Mar/2026
Prestige Brands USD 2.02B 1.01B Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
Sanofi EUR 12.3B 3.42B Mar/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
Zoetis USD 9.05B 3M Jun/2026